Servier in cancer, autoimmune deals in Singapore
Servier (Neuilly-sur-Seine, France) signed three research collaborations with the Singapore Immunology Network (SIgN) to discover and develop compounds for indications including cancer and autoimmune diseases. Under two of the deals, SIgN will use dendritic cell biology to develop therapies for cancer, organ transplantation, inflammation and autoimmune diseases. The third deal will focus on identifying genetic dispositions in Asian patients related to drug-induced side effects. Servier said SIgN would be responsible for discovery research, and that Servier will have rights to develop resulting compounds. The company declined to disclose additional details, including targets and financial terms. SIgN, which could not be reached for comment, is a research unit of the Singapore Agency for Science, Technology and Research (A*STAR). ...